Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinically relevant composite: Death
Timeframe: From date of randomization up to a minimum of 2 years
Clinically relevant composite: Retransplant
Timeframe: From date of randomization up to a minimum of 2 years
Clinically relevant composite: Allograft Dysfunction
Timeframe: From date of randomization up to a minimum of 2 years
Clinically relevant composite: CAV with Heart Failure or Myocardial Infarction
Timeframe: From date of randomization up to a minimum of 2 years